Ishimoto U et al. - To date, no clinically useful prognostic factors have been reported for patients with advanced intrahepatic cholangiocarcinoma (ICC). In the current study, the clinical prognostic factors of patients with advanced ICC receiving gemcitabine plus cisplatin combination therapy (GC) were evaluated.

Methods

• A retrospective analysis of patients with ICC was conducted.

Results

• Of 216 patients with biliary tract cancer receiving GC as first-line chemotherapy, 77 patients who were diagnosed with ICC and received GC as first-line chemotherapy were studied.
• The median overall survival was 13.8 months.
• Pretreatment serum lactate dehydrogenase (HR = 2.53), C-reactive protein (HR = 3.06), and carcinoembryonic antigen (HR = 2.39) levels were significantly associated with overall survival.